Skip to main content

Vericel Value Stock - Dividend - Research Selection

Vericel

ISIN: US92346J1088 , WKN: A12FU4

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Insider Sell: Chief Medical Officer Jonathan Hopper Sells 5,000 Shares of Vericel Corp (VCEL)

2023-11-23
Vericel Corp (NASDAQ:VCEL), a leader in the field of regenerative medicine, has recently seen a significant insider transaction.

Vericel’s Growth Potential and Distinct Product Profiles: The Basis for a Buy Rating

2023-11-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects

2023-11-17
Delcath's Hepzato Kit, a liver-directed treatment for rare cancer, is set to launch in the US in January. Read why I am bullish on DCTH stock.

3 Biotech Stocks That Could Boom or Bust by 2025

2023-11-16
InvestorPlace published an article last December about the seven hottest biotech stocks to own in 2023 and beyond. One of the seven was the SPDR S&P Biotech ETF (NYSEARCA:XBI). XBI tracks the performance of the S&P Biotechnology Select Industry Index which represents the biotechnology sub-sector of the S&P Total Market Index. XBI currently has 133 holdings. The index is equal-weighted so that smaller biotech stocks can make it into the portfolio. The index and exchange-traded fund ETF are rebala

Conestoga Capital Advisors Q3 2023 Commentary

2023-11-15
Conestoga’s four primary investment strategies posted mixed results for the quarter. Click here to read the full fund letter.

3 Strong Buy Stocks Set to Take Off in the Coming Months

2023-11-11
Some of the most followed information in the stock market besides earnings releases are analyst recommendations. These are expert analyses that cover various companies that have a high potential for return on investment or industries in which they specialize. These recommendations can go from “Strong Sell” to “Strong Buy,” and most investors look for Strong Buy stocks to help bolster their portfolio growth. While a strong buy may sound encouraging, it is imperative for investors to still conduct

Vericel Stock’s Promising Outlook: Buy Rating, Increased Price Target, and High-Growth MedTech Potential

2023-11-10
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript

2023-11-09
Vericel Corporation (NASDAQ:VCEL) Q3 2023 Earnings Call Transcript November 8, 2023 Vericel Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.13. Operator: Ladies and gentlemen, thank you for standing by. Welcome to Vericel’s Third Quarter 2023 conference call. At this time, all participants are in a listen-only mode. I would also like remind […]

Hold Rating on Vericel: A Measured Approach on Future Growth Amid Slower NexoBrid Ramp and Valuation Concerns

2023-11-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Vericel price target raised to $39 from $33 at Truist

2023-11-09
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.